FibroBiologics, Inc. 8-K

What Happened

• FibroBiologics, Inc. announced it closed a best‑efforts public offering on April 2, 2026. The offering sold 1,028,788 shares of common stock, pre‑funded warrants to purchase up to 1,243,940 shares, and warrants exercisable for up to 2,272,728 shares (combined totals as offered). The combined public offering price was $1.32 per share plus accompanying warrant (pre‑funded units priced at $1.31999). Net proceeds to the company were approximately $2.5 million after placement agent fees and offering expenses. If the warrants are later exercised for cash following stockholder approval, the company would receive up to an additional ~$3.0 million (exercise price $1.32 per warrant), but exercise is uncertain and may be cashless.

Key Details

• Offering closed April 2, 2026 under the company’s Form S‑1 (effective March 31, 2026); purchase agreements dated March 31, 2026.
• Net proceeds: ~ $2.5 million; potential additional gross proceeds if warrants exercised for cash: ~ $3.0 million.
• Placement agent (H.C. Wainwright & Co.) compensation: 7.0% cash fee + 1.0% management fee of aggregate purchase price, $100,000 legal fee reimbursement, and placement agent warrants to purchase up to 159,091 shares at $1.65 (7% of shares sold). Placement agent warrants and investor warrants are subject to stockholder approval and expire five years from commencement of sales (placement agent warrants).
• Key warrant terms: investor warrants exercise price $1.32; pre‑funded warrants exercisable at $0.00001 per share, no expiration; ownership caps on exercise (4.99% for warrants, 9.99% for pre‑funded warrants); warrants may be cashless if no effective resale registration.

Why It Matters

• The financing provides immediate working capital and general corporate funds (~$2.5M net) to support operations. However, the potential dilution from outstanding warrants and placement agent warrants could be material if exercised — and the company’s ability to realize the additional ~$3.0M depends on future stockholder approval and whether holders choose cash or cashless exercise. Investors should note the usual lock‑up and issuance restrictions (30‑day lock‑up for insiders, a one‑year restriction on certain variable rate transactions) and the placement agent’s compensation, which reduces net proceeds.